Core Viewpoint - The company, Huaren Health, announced that its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration [1] Group 1: Product Information - Fumaric Acid Vonoprazan Tablets are a new type of potassium ion competitive acid blocker (P-CAB) [1] - The drug can reversibly inhibit the H+/K+-ATPase on gastric parietal cells in a potassium ion competitive manner without relying on an acidic environment [1] - It is stable in highly acidic environments and can quickly, effectively, and durably suppress gastric acid secretion from gastric parietal cells, significantly reducing the occurrence of nighttime gastric acid elevation [1]
华人健康(301408.SZ)：富马酸伏诺拉生片药品注册上市许可申请获受理